Efavirenz (also known as Sustiva) is a nucleoside reverse transcriptase inhibitor (NRTI) for treating HIV infection by inhibiting the transcriptase reversibly. Efavirenz is phosphorylated to its active triphosphorylated form so that it can compete with deoxycytidine 5'-triphosphate to inhibit HIV-1 reverse transcriptase, which lead to early chain termination.
References
Efavirenz Pathway References
Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure. 2000 Oct 15;8(10):1089-94.
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
